Been in this for a little while now since the change in market structure and added a few times to this position so not the best avg weighted entry but still well in profit.
Classic sweep of lows and change in market structure has me excited on this position and more recently over the last month with the gap up above the previous short term high and now the...
After a nice pullback im thinking we may have the higher low set, certainly possible we make a larger correction but I added on that higher low expecting the follow through at some point.
Watching the rising wedge for potential exit signs and a larger potential top 3rd wave top.
Clearly a lot of value has been lost in the past month. The CSO stepped down and analysts downgraded projected revenue. EDIT has very lucrative candidates in the pipeline treating sickle cell anemia. Long-term, this company will most certainly be profitable, with significant patent protection. This is a short term down draft that is consolidating, for the near...
Hello all, Notice MACD, RSI and 50 day MA trends for EDIT. I am planning to accumulate calls this week and some last week to play the bounce signaled by RSI and MACD into the JPM healthcare conference on the 15th where these biotechs present promising results and play pop.
Plus biotech is a risky defensive bet - mutually exclusive of Iran - these biotechs are...
Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment...
NTLA has been flying through resistance levels from oversold conditions and looks like it's testing 17.28 resistance to establish it as support. If it closes above, likely going higher - if it rejects off of 17.28 then likely retest of high 15s before re-testing 17s. Apart from ongoing patent battles, this company was hit by a scientific paper that made unfounded...
Nice support level at $20
Filled Gap up and Gap down.
If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels.
CRISPR got upgraded.
EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing...
